Global Medical REIT Inc. (GMRE) Financial Ratios
14 years of historical data (2012–2025) · Real Estate · REIT - Healthcare Facilities
EV/EBITDA
↓
8.35
+4% vs avg
5yr avg: 7.99
30Y Low5.7·High13.6
P/FCF
↑
N/A
—
5yr avg: 4.31
30Y Low2.5·High6.1
P/B Ratio
↑
0.17
↓-53% vs avg
5yr avg: 0.36
30Y Low0.1·High0.9
ROE
↓
-2.2%
↑-233% vs avg
5yr avg: 1.7%
30Y Low-185%·High5%
Debt/EBITDA
↑
N/A
—
5yr avg: 7.00
30Y Low5.4·High11.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GMRE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Global Medical REIT Inc. trades at 115.3x earnings, 91% above its 5-year average of 60.2x, sitting at the 75th percentile of its historical range. Compared to the Real Estate sector median P/E of 24.1x, the stock trades at a premium of 379%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $94M | $451M | $102M | $146M | $124M | $215M | $121M | $90M | $39M | $32M | $17M |
| Enterprise Value | $741M | $442M | $749M | $768M | $825M | $788M | $723M | $482M | $350M | $231M | $63M |
| P/E Ratio → | 115.29 | — | 124.52 | 9.65 | 46.47 | — | — | — | 2.91 | — | — |
| P/S Ratio | 0.68 | 3.05 | 0.74 | 1.03 | 0.90 | 1.86 | 1.29 | 1.27 | 0.73 | 1.06 | 2.05 |
| P/B Ratio | 0.17 | 0.85 | 0.18 | 0.24 | 0.19 | 0.34 | 0.26 | 0.19 | 0.13 | 0.12 | 0.08 |
| P/FCF | — | 6.13 | — | 2.49 | — | — | — | — | — | — | — |
| P/OCF | 1.35 | 6.13 | 1.45 | 2.13 | 1.62 | 3.12 | 3.50 | 2.46 | 1.57 | 2.77 | — |
P/E links to full P/E history page with 30-year chart
GMRE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Global Medical REIT Inc.'s enterprise value stands at 8.3x EBITDA, roughly in line with its 5-year average of 8.0x. The Real Estate sector median is 17.0x, placing the stock at a 51% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.98 | 5.41 | 5.45 | 6.01 | 6.80 | 7.73 | 6.81 | 6.59 | 7.63 | 7.85 |
| EV / EBITDA | 8.35 | 5.69 | 8.43 | 7.93 | 8.56 | 9.35 | 13.64 | 6.54 | 6.54 | 7.60 | 7.73 |
| EV / EBIT | 22.68 | 22.52 | 21.16 | 14.60 | 18.24 | 20.71 | 44.68 | 17.81 | 11.86 | 31.37 | — |
| EV / FCF | — | 6.01 | — | 13.16 | — | — | — | — | — | — | — |
GMRE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from 26.9% to 23.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -2.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 78.9% | 80.1% | 81.6% | 86.6% | 88.4% | 90.8% | 93.0% | 93.8% | 82.3% |
| Operating Margin | — | — | 23.6% | 26.9% | 28.2% | 31.9% | — | 70.6% | 41.8% | 24.3% | -27.4% |
| Net Profit Margin | -8.2% | -8.2% | 4.8% | 14.6% | 14.0% | 15.2% | -2.1% | 13.1% | 25.4% | -0.1% | -78.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2.2% | -2.2% | 1.1% | 3.3% | 3.0% | 3.2% | -0.4% | 2.4% | 4.8% | -0.0% | -6.4% |
| ROA | -1.0% | -1.0% | 0.5% | 1.5% | 1.4% | 1.5% | -0.2% | 1.2% | 2.4% | -0.0% | -4.3% |
| ROIC | — | — | 2.0% | 2.2% | 2.3% | 2.4% | — | 5.1% | 3.1% | 1.6% | -1.1% |
| ROCE | — | — | 5.3% | 5.5% | 5.4% | 4.1% | — | 8.3% | 6.9% | 3.0% | -1.7% |
GMRE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 0.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 1.18 | 1.03 | 1.09 | 0.91 | 1.33 | 0.86 | 1.05 | 0.79 | 0.33 |
| Debt / EBITDA | — | — | 7.36 | 6.44 | 7.31 | 6.88 | 11.46 | 5.36 | 5.88 | 6.70 | 8.10 |
| Net Debt / Equity | — | -0.02 | 1.16 | 1.03 | 1.08 | 0.90 | 1.32 | 0.85 | 1.04 | 0.77 | 0.23 |
| Net Debt / EBITDA | -0.12 | -0.12 | 7.29 | 6.43 | 7.27 | 6.79 | 11.36 | 5.32 | 5.81 | 6.54 | 5.71 |
| Debt / FCF | — | -0.12 | — | 10.67 | — | — | — | — | — | — | — |
| Interest Coverage | 0.62 | 0.62 | 1.23 | 1.70 | 1.79 | 1.93 | 0.87 | 1.55 | 1.97 | 0.99 | -0.53 |
Net cash position: cash ($9M) exceeds total debt ($0)
GMRE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 0.03 | 0.02 | 0.05 | 0.05 | 1.11 | 1.30 | 0.03 | 0.05 | 0.68 |
| Quick Ratio | — | — | 0.03 | 0.02 | 0.05 | 0.05 | 1.11 | 1.30 | 0.03 | 2.75 | 0.65 |
| Cash Ratio | — | — | 0.01 | 0.00 | 0.01 | 0.01 | 0.15 | 0.11 | 0.01 | 0.03 | 0.61 |
| Asset Turnover | — | 0.12 | 0.11 | 0.11 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.06 | 0.04 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 1.52 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
GMRE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Global Medical REIT Inc. returns 63.5% to shareholders annually primarily through dividends. The earnings yield of 0.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 63.5% | 11.6% | 58.8% | 40.6% | 47.1% | 24.4% | 33.1% | 32.6% | 48.5% | 47.3% | 23.4% |
| Payout Ratio | — | — | 902.6% | 286.4% | 305.2% | 297.9% | — | 315.9% | 140.6% | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.9% | — | 0.8% | 10.4% | 2.2% | — | — | — | 34.3% | — | — |
| FCF Yield | — | 16.3% | — | 40.1% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% |
| Total Shareholder Yield | 63.5% | 12.9% | 58.8% | 40.6% | 47.1% | 24.4% | 33.1% | 32.6% | 49.2% | 47.3% | 23.4% |
| Shares Outstanding | — | $13M | $3M | $3M | $3M | $2M | $2M | $1M | $878840 | $784680 | $372080 |
Peer Comparison
Compare GMRE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GMREYou | $94M | 115.3 | 8.3 | — | — | — | -2.2% | — | — |
 CHCT | $498M | 225.2 | 16.2 | 8.8 | 8.7% | 16.7% | 1.1% | 1.6% | 8.4 |
 NXRT | $684M | -21.4 | 18.0 | 8.2 | 84.3% | 11.1% | -8.9% | 1.1% | 12.6 |
 PLYM | $979M | 7.1 | 13.3 | 10.2 | 68.9% | 18.2% | 25.9% | 2.1% | 5.4 |
 HR | $7B | -27.9 | 16.7 | 54.4 | -33.6% | 8.0% | -4.9% | 0.7% | 6.3 |
 DOC | $14B | 195.6 | 14.7 | 11.9 | 22.5% | 19.3% | 0.8% | 2.3% | 6.5 |
 MPW | $3B | -17.1 | 105.4 | 14.6 | — | — | -4.2% | — | 4.6 |
 OHI | $13B | 23.0 | 16.3 | 15.1 | 44.5% | 62.6% | 11.6% | 6.0% | 4.0 |
 SBRA | $5B | 28.3 | 15.6 | 13.1 | 65.0% | 34.1% | 5.6% | 3.8% | 5.7 |
 LTC | $2B | 14.4 | 16.4 | 13.7 | 75.1% | 48.2% | 10.7% | 5.1% | 5.1 |
 CTRE | $9B | 23.6 | 22.9 | 23.1 | 59.1% | 67.2% | 9.2% | 6.1% | 2.2 |
| Real Estate Median | — | 24.1 | 17.0 | 15.4 | 49.3% | 24.8% | 3.7% | 2.7% | 7.9 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
GMRE — Frequently Asked Questions
Quick answers to the most common questions about buying GMRE stock.
What is Global Medical REIT Inc.'s P/E ratio?
Global Medical REIT Inc.'s current P/E ratio is 115.3x. The historical average is 45.9x. This places it at the 75th percentile of its historical range.
What is Global Medical REIT Inc.'s EV/EBITDA?
Global Medical REIT Inc.'s current EV/EBITDA is 8.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 8.2x.
What is Global Medical REIT Inc.'s ROE?
Global Medical REIT Inc.'s return on equity (ROE) is -2.2%. The historical average is -20.6%.
Is GMRE stock overvalued?
Based on historical data, Global Medical REIT Inc. is trading at a P/E of 115.3x. This is at the 75th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Global Medical REIT Inc.'s dividend yield?
Global Medical REIT Inc.'s current dividend yield is 63.51%.